Budget removal key to German diagnostic industry revival
This article was originally published in Clinica
Executive Summary
The chairman of the German diagnostics industry association (VDGH), Volker Oeding, last week launched a blistering attack on the federal association of statutory health insurance physicians (KBV) and the leading groups of the statutory health insurance funds (GKV) whose budgetary policies were unnecessarily driving up the costs of the health service by denying the public the benefits of laboratory diagnostics. Speaking at a conference marking the 25th anniversary of VDGH in Berlin, Dr Oeding said: "The health service cannot be saved by senseless cost-cutting, but rather through the intelligent distribution of available resources."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.